AbbVie to acquire ImmunoGen for $10.1B

AbbVie Inc. said on Thursday that it will pay $10.1 billion to acquire ImmunoGen Inc. and its flagship cancer treatment, Elahere, which is used to treat ovarian cancer. The transaction is anticipated …